| Today’s Big NewsFeb 28, 2025 |
| By Darren Incorvaia The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.65 billion to develop new versions of the sticky molecules in collaboration with Magnet Biomedicine. |
|
|
|
By James Waldron For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. While interest in this path has died down in recent years, BridgeBio’s former cancer unit thinks it could work for them. |
By Nick Paul Taylor Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after Praxis CEO Marcio Souza said the chances of the trial being futile were “less than 3%,” the biotech has learnt the study looks unlikely to meet its primary endpoint at an interim analysis. |
Sponsored by Sciensus Avoid common pitfalls in EU orphan drug market access—learn how local expertise can help navigate pricing, reimbursement, and regulatory hurdles. |
|
BioIVT offers different tiered options to quickly customize your drug metabolism and drug-drug interaction study designs, but how do you know which matches your needs and end goals? Learn More >>
|
|
By Nick Paul Taylor AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a preclinical laboratory in the U.K. to focus on its two clinical candidates. |
Sponsored by Fortrea Fortrea's CTO discusses AI's expanding role in clinical trials, from discovery to execution, and its potential to improve patient outcomes and diversity. |
By James Waldron Nxera Pharma has sold the Asia-Pacific rights to its phase 3 autoimmune drug to Viatris for $10 million upfront. |
By Darren Incorvaia,Zoey Becker Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a buyout that went for $3 per share. Mirati and Ipsen’s former CEO David Meek, who currently chairs Sobi, will take the reins at bluebird upon the deal’s close, which is expected to be in the first half of this year. |
By Andrea Park,Darren Incorvaia This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
By Noah Tong The Trump administration is moving urgently to remake health departments in its vision. Federal workers worry the actions will impair the nation’s healthcare system in countless ways, |
By Kevin Dunleavy For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed that she took a 16% pay cut in 2024, it also laid out a new compensation plan which could make her one of the highest-paid chief executives in the industry this year. |
By Paige Minemyer A rumored private equity buyout of Walgreens could lead the company to be split up, according to media reports. |
By Angus Liu Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. Pfizer has formed a clinical trial collaboration with Akeso's partner Summit Therapeutics. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
|
|---|
|
|
| Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
